Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
XENE logo XENE
Upturn stock ratingUpturn stock rating
XENE logo

Xenon Pharmaceuticals Inc (XENE)

Upturn stock ratingUpturn stock rating
$37.96
Last Close (24-hour delay)
Profit since last BUY11.29%
upturn advisory
Consider higher Upturn Star rating
BUY since 4 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: XENE (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

19 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $55.06

1 Year Target Price $55.06

Analysts Price Target For last 52 week
$55.06 Target price
52w Low $26.74
Current$37.96
52w High $46

Analysis of Past Performance

Type Stock
Historic Profit -27.03%
Avg. Invested days 23
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.93B USD
Price to earnings Ratio -
1Y Target Price 55.06
Price to earnings Ratio -
1Y Target Price 55.06
Volume (30-day avg) 19
Beta 1.17
52 Weeks Range 26.74 - 46.00
Updated Date 08/15/2025
52 Weeks Range 26.74 - 46.00
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.55

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-08-11
When -
Estimate -0.99
Actual 1.07

Profitability

Profit Margin -
Operating Margin (TTM) -969.84%

Management Effectiveness

Return on Assets (TTM) -22.03%
Return on Equity (TTM) -31.6%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2448106130
Price to Sales(TTM) 390.26
Enterprise Value 2448106130
Price to Sales(TTM) 390.26
Enterprise Value to Revenue 326.41
Enterprise Value to EBITDA -11.81
Shares Outstanding 77105800
Shares Floating 70881895
Shares Outstanding 77105800
Shares Floating 70881895
Percent Insiders 0.14
Percent Institutions 105.56

ai summary icon Upturn AI SWOT

Xenon Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Xenon Pharmaceuticals Inc. is a biopharmaceutical company founded in 1996. It focuses on developing novel therapeutics for neurological disorders. The company has evolved from a genomics-based research firm to a clinical-stage biopharmaceutical developer.

business area logo Core Business Areas

  • Neurology: Focuses on developing therapies for epilepsy and other neurological disorders.
  • Rare Diseases: Development of therapies for rare neurological disorders.
  • Preclinical Programs: Discovery and development of novel therapeutic candidates in various areas.

leadership logo Leadership and Structure

The leadership team includes Ian Mortimer (President and CEO). The company is structured around research, clinical development, and commercialization functions.

Top Products and Market Share

overview logo Key Offerings

  • XEN1101 (active epilepsy): A Kv7 potassium channel modulator being developed for the treatment of focal epilepsy. Phase 3 clinical trials are underway. Competitors include generic anti-epileptic drugs (AEDs) and newer branded AEDs from companies like UCB, Eisai, and SK Biopharmaceuticals. Estimated revenue not publicly discolsed. Market share is still emerging.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. There is a significant unmet need for novel therapies in neurological disorders.

Positioning

Xenon is positioned as a specialty biopharmaceutical company focused on novel mechanisms of action in specific neurological indications. Their competitive advantage lies in their expertise in Kv7 potassium channel modulation.

Total Addressable Market (TAM)

The TAM for epilepsy treatments is estimated to be billions of dollars annually. Xenon is positioned to capture a portion of this market with XEN1101 if approved.

Upturn SWOT Analysis

Strengths

  • Strong expertise in Kv7 potassium channel modulation
  • Promising clinical pipeline
  • Experienced management team
  • Strong intellectual property position

Weaknesses

  • Reliance on a limited number of clinical programs
  • High R&D expenses
  • Dependence on regulatory approvals
  • Limited commercial infrastructure

Opportunities

  • Successful clinical trials for XEN1101
  • Expansion into new neurological indications
  • Partnerships with larger pharmaceutical companies
  • Advancements in precision medicine

Threats

  • Clinical trial failures
  • Regulatory setbacks
  • Competition from established pharmaceutical companies
  • Generic erosion of existing products

Competitors and Market Share

competitor logo Key Competitors

  • UCB (UCBJF)
  • Eisai (ESALY)
  • SK Biopharmaceuticals (326030.KS)

Competitive Landscape

Xenon faces competition from established pharmaceutical companies with broader product portfolios and more extensive commercial infrastructure. Xenon's advantage lies in its focus on novel mechanisms of action and specific neurological indications.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited due to the lack of commercial products. The company's growth is primarily reflected in the expansion of its clinical pipeline.

Future Projections: Future growth is highly dependent on the successful development and commercialization of XEN1101 and other pipeline candidates. Analyst estimates vary widely depending on the perceived likelihood of success.

Recent Initiatives: Recent initiatives include the ongoing Phase 3 clinical trials for XEN1101 and the advancement of preclinical programs.

Summary

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on neurological disorders. The success of XEN1101 is critical to the company's future. While Xenon possesses strengths in Kv7 potassium channel modulation and a promising clinical pipeline, it faces risks associated with clinical trials, regulatory approvals, and competition. Future growth is contingent upon successfully navigating these challenges and capitalizing on opportunities in the neurology space.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Xenon Pharmaceuticals Inc. Investor Relations
  • Company SEC Filings
  • Analyst Reports
  • Industry Publications

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Xenon Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Burnaby, BC, Canada
IPO Launch date 2014-11-05
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 316
Full time employees 316

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.